MARKET

CLBS

CLBS

Caladrius
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.030
+0.030
+1.50%
After Hours: 2.060 +0.03 +1.48% 18:11 07/10 EDT
OPEN
1.980
PREV CLOSE
2.000
HIGH
2.070
LOW
1.920
VOLUME
340.57K
TURNOVER
--
52 WEEK HIGH
3.640
52 WEEK LOW
1.050
MARKET CAP
31.57M
P/E (TTM)
-1.1189
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CLBS stock price target is 10.50 with a high estimate of 18.50 and a low estimate of 6.00.

EPS

CLBS News

More
Caladrius Biosciences to Present on CLBS119 for COVID-19 Induced Lung Damage at the BioNJ COVID-19 Rapid Fire Research Showcase
GlobeNewswire · 06/02 13:06
Caladrius Biosciences Closes $4.3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
GlobeNewswire · 05/28 18:20
96 Biggest Movers From Yesterday
Gainers Mmtec, Inc. (NASDAQ: MTC) shares climbed 86.4% to close at $2.05 on Tuesday after reporting its financial results for the year ended December 31, 2019. Revenues jumped 647% to $200,797, in 2019.
Benzinga · 05/27 08:20
Mid-Afternoon Market Update: Crude Oil Up 2%; argenx Shares Spike Higher
Toward the end of trading Tuesday, the Dow traded up 2.80% to 25150.26 while the NASDAQ rose 0.99% to 9417.08. The S&P also rose, gaining 1.94% to 3012.86.
Benzinga · 05/26 18:32
Mid-Morning Market Update: Markets Open Higher; AutoZone Beats Q3 Expectations
Following the market opening Tuesday, the Dow traded up 2.29% to 25024.78 while the NASDAQ rose 1.38% to 9453.15. The S&P also rose, gaining 1.77% to 3007.81.
Benzinga · 05/26 18:15
Mid-Day Market Update: Dow Jumps Over 600 Points; BioLineRx Shares Plunge
Midway through trading Tuesday, the Dow traded up 2.66% to 25116.29 while the NASDAQ rose 1.07% to 9424.75. The S&P also rose, gaining 1.90% to 3011.70.
Benzinga · 05/26 18:15
LK, ALT, CLBS and BLRX among midday movers
Seeking Alpha - Article · 05/26 16:43
61 Stocks Moving In Tuesday's Mid-Day Session
Gainers Mmtec, Inc. (NASDAQ: MTC) shares jumped 98.2% to $2.18 in pre-market trading after reporting its financial results for the year ended December 31, 2019. Revenues jumped 647% to $200,797, in 2019.
Benzinga · 05/26 16:29

Industry

Biotechnology & Medical Research
-0.39%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Symbol
Price
%Change

About CLBS

Caladrius Biosciences, Inc. is a late-stage therapeutics development biopharmaceutical company that provides cell therapies for cardiovascular and autoimmune diseases. The Company’s product candidates include three developmental treatments for cardiovascular diseases based on its classification determinant34+ (CD34+) cell therapy platform. Its CLBS12 product candidate is a recipient of a SAKIGAKE designation in Japan and advanced therapy medicinal product classification (ATMP) in Europe. Its CLBS16 product candidate is being developed for the treatment of coronary microvascular dysfunction (CMD). Its CLBS14 product candidate is a phase III ready clinical program in no option refractory disabling angina. CLBS14 is a recipient of a regenerative medicine advanced therapy (RMAT) designation in the United States. It also has an autoimmune product candidate, CLBS03, which is being developed for the treatment of type I diabetes.
More

Webull offers kinds of Caladrius Biosciences Inc stock information, including NASDAQ:CLBS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLBS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CLBS stock methods without spending real money on the virtual paper trading platform.